Originally published In Press as doi:10.1074/jbc.M201164200 on March 13, 2002
J. Biol. Chem., Vol. 277, Issue 21, 18552-18560, May 24, 2002
Environment and Mobility of a Series of Fluorescent Reporters at
the Amino Terminus of Structurally Related Peptide Agonists and
Antagonists Bound to the Cholecystokinin Receptor*
Kaleeckal G.
Harikumar,
Delia I.
Pinon,
William S.
Wessels,
Franklyn G.
Prendergast, and
Laurence J.
Miller
From the Department of Molecular Pharmacology and Experimental
Therapeutics, Mayo Clinic and Foundation, Rochester, Minnesota
55905
Received for publication, February 5, 2002
 |
ABSTRACT |
Fluorescence is a powerful biophysical tool for
the analysis of the structure and dynamics of proteins. Here, we have
developed two series of new fluorescent probes of the cholecystokinin
(CCK) receptor, representing structurally related peptide agonists and antagonists. Each ligand had one of three distinct fluorophores (Alexa488, nitrobenzoxadiazolyl, or
acrylodan) incorporated in analogous positions at the amino terminus
just outside the hormone's pharmacophore. All of the probes bound to
the CCK receptor specifically and with high affinity, and intracellular
calcium signaling studies showed the chemically modified peptides to be
fully biologically active. Quenching by iodide and measurement of
fluorescence spectra, anisotropy, and lifetimes were used to
characterize the response of the fluorescence of the probe in the
peptide-receptor complex for agonists and antagonists. All three
fluorescence indicators provided the same insights into differences in
the environment of the same indicator in the analogous position for
agonist and antagonist peptides bound to the CCK receptor. Each agonist
had its fluorescence quenched more easily and showed lower anisotropy
(higher mobility of the probe) and shorter lifetime than the analogous
antagonist. Treatment of agonist-occupied receptors with a
non-hydrolyzable GTP analogue shifted the receptor into its inactive
low affinity state and increased probe fluorescence lifetimes toward
values observed with antagonist probes. These data are consistent with
a molecular conformational change associated with receptor activation
that causes the amino terminus of the ligand (situated above
transmembrane segment six) to move away from its somewhat protected
environment and toward the aqueous milieu.
 |
INTRODUCTION |
Cell surface receptors present on essentially every excitable cell
of the body are important targets for pharmacotherapy. A detailed
understanding of the structure of these molecules and the molecular
basis of their activation should contribute to the rational design and
refinement of ligands for these receptors. Receptor-bound,
environmentally sensitive fluorescent reporters can provide information
regarding ligand-binding domains (1). In this work, we utilize this
approach to gain insight into agonist- and antagonist-binding domains
of the type A cholecystokinin
(CCK)1 receptor, a
physiologically important member of the rhodopsin/
-adrenergic receptor family of guanine nucleotide-binding protein (G
protein)-coupled receptors.
The superfamily of G protein-coupled receptors represents the largest
group of membrane receptors. They are remarkable for the diversity in
structure of the natural agonist ligands that can activate them and
initiate intracellular signaling cascades. These range in size from
small photons and odorants to peptides, proteins, and even large viral
particles. Tertiary structure determination by x-ray crystallography
has provided the most incisive insight into the structure of
superfamily members, which bind small ligands in the intramembranous
helical bundle domain (2). As the ligands get larger, receptor domains
involved in binding tend to be located on the extramembranous portion
of the receptor, i.e. in the external tail and loop domains
(3, 4). However, our understanding of the molecular details of the
binding of such ligands and mechanisms of receptor activation are still limited.
We have been interested in the CCK receptor that is activated by a
natural peptide hormone. This is a physiologically important receptor
involved in regulating various processes related to nutrient homeostasis. Its activation stimulates gallbladder contraction, stimulates pancreatic exocrine secretion, inhibits gastric emptying, and elicits satiety. Consistent with the theme described above, mutagenesis and photoaffinity labeling studies have suggested the
importance of loop and tail domains of this receptor for CCK binding
(5-8). Although such studies provide useful insights for the docking
of ligand to receptor to establish a conformational complex, they
provide little information about the presumed conformational changes
occurring upon receptor activation.
In this report, we have used fluorescence to gain insight into
differences between active and inactive conformations of the receptor.
We have developed two series of fluorescent probes, built on
structurally related peptide agonist and antagonist of the CCK
receptor, placing three distinct fluorescence indicators in analogous
positions. The fluorophore was positioned at the amino terminus of
these probes, just outside of the pharmacophore of the ligand. This
location of the probe was critical to accommodate the relatively bulky
and structurally diverse fluorophores without disturbing agonist or
antagonist action. We had previously shown that a photolabile moiety
incorporated into an analogous position in peptide full agonist,
partial agonist, and antagonist of the CCK receptor allowed retention
of biologic effect, and, moreover, the probes covalently labeled the
same general domain of the receptor (cyanogen bromide fragment) (9).
Fluorescent probes similarly placed should provide more sensitive
indicators of the microenvironment and mobility of this site, and allow
comparisons of how this receptor's conformation adapts to agonist or
antagonist binding, i.e. information on conformational
features of the active and inactive states of this receptor.
The results suggest that the fluorophore in this position in the probes
sensed different environments depending, apparently, on the
hydrophilicity or hydrophobicity of the fluorophore and the nature of
the ligand. Despite apparently occupying distinctive environments, the
behavior of the probes showed consistent patterns for the active and
inactive receptor states, respectively. We inferred that, upon receptor
activation, the amino terminus of the peptide ligand was more exposed
to the aqueous solvent and further removed from the lipid bilayer.
Treatment with non-hydrolyzable GTP analogues that shift the
agonist-occupied receptor into its inactive low affinity state (10)
moved the amino terminus of the peptide ligand back into a more
protected environment, analogous to the position it occupied in the
antagonist peptide.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Synthetic CCK-8 was purchased from Peninsula
Laboratories (Belmont, CA). Fura-2AM, acrylodan, NBD-aminocaproic
acid-N-hydroxysuccinimide ester, and
Alexa488-N-hydroxysuccinimide ester were from
Molecular Probes (Eugene, OR). Fetal clone 2 was from HyClone
Laboratories (Logan, UT).
Synthesis of Fluorescent CCK Receptor Probes--
Probe
design was based on established structure-activity considerations for
CCK analogues (11-13). We designed two series of peptides,
representing agonists and antagonists of the CCK receptor, that
incorporated three different fluorescent reporter groups in analogous
positions, at the amino terminus, just outside of the hormone
pharmacophore (Fig. 1). The agonist
probes utilized Gly-[(Nle28,31)CCK-26-33] (14) as
template, whereas the antagonist probes utilized
Gly-[(D-Trp30,Nle28,31)CCK-26-32]-phenylethyl
ester (D-Trp-OPE) (15) as template. The fluorophores
included Alexa488, acrylodan, and
nitrobenzoxadiazolylaminocaproic acid (NBD-aca), with each
possessing distinct chemical and fluorescence characteristics. These
range from most hydrophobic (acrylodan) to most hydrophilic (Alexa).
Each is sensitive to the polarity of its environment. Full structures
include the following:
Alexa488-Gly-[(Nle28,31)CCK-26-33]
(Alexa-agonist),
acrylodan-Cys-Gly-[(Nle28,31)CCK-26-33]
(acrylodan-agonist), NBD-aca-Gly-[(Nle28,31)CCK-26-33]
(NBD-agonist),
Alexa488-Gly-[(D-Trp30,Nle28,31)CCK-26-32]-phenylethyl
ester (Alexa-antagonist),
acrylodan-Cys-Gly-[(D-Trp30,Nle28,31)CCK-26-32]-phenylethyl
ester (acrylodan-antagonist), and
NBDaca-Gly-[(D-Trp30,Nle28,31)CCK-26-32]-phenylethyl
ester (NBDantagonist).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 1.
Probe structure. Shown are the chemical
structures of the fluorescence indicators placed at the amino terminus
of CCK receptor probes, in position 24 using the CCK-33 numbering
scheme. Also shown are the peptide agonist,
Gly-[(Nle28,31)CCK-26-33], and antagonist,
Gly-[(D-Trp30,Nle28,31)CCK-26-32]-phenylethyl
ester, used as templates for the two series of probes.
|
|
In the synthesis, Gly-[(Nle28,31)CCK-26-33] and
Gly-[(D-Trp30,Nle28,31)CCK-26-32]-phenylethyl
ester were prepared as previously reported (14-16). Both peptides have
only a single reactive amino group. For each probe, the free amino
group was derivatized in solution with N-hydroxysuccinimide
esters of Alexa488, Fmoc-cysteine, or NBD-aminocaproic
acid. For the acrylodan probes, the Fmoc-cysteine peptides were allowed
to react with acrylodan and were deprotected. Each of the peptides was
purified to homogeneity by reversed-phase HPLC, and was characterized
by mass spectrometry.
Receptor Preparations--
The Chinese hamster ovary cell line
that was engineered to express the rat type A CCK receptor (CHO-CCKR)
was used as a source for receptor in this study (17). This cell line
has previously been fully characterized, establishing its expression of
functional receptors that bind CCK and signal normally (17). Cells were grown in tissue culture flasks containing Ham's F-12 medium
supplemented with 5% Fetal clone 2 in a humidified environment
containing 5% carbon dioxide. Cells were passaged approximately two
times per week.
A particulate fraction enriched in plasma membranes was prepared from
semi-confluent cells by mixing the cell suspension with 0.3 M sucrose containing 0.01% soybean trypsin inhibitor and 1 mM phenylmethylsulfonyl fluoride and sonicating for 10 s at setting 7 with a Sonifier Cell Disrupter (Heat
Systems-Ultrasonics, Inc., Plainview, NY). The sucrose concentration of
the cell suspension was adjusted to 1.3 M, placed at the
bottom of a tube, and overlayered with 0.3 M sucrose prior
to centrifugation at 225,000 × g for 1 h at
4 °C. The enriched membrane band at the sucrose interface was then
harvested, diluted with ice-cold water, and pelleted by centrifugation
at 225,000 × g for 30 min. Membranes were then re-suspended in Krebs-Ringers-HEPES (KRH) medium containing 25 mM HEPES, pH 7.4, 104 mM NaCl, 5 mM
KCl, 2 mM CaCl2, 1 mM
KH2PO4, 1.2 mM MgSO4,
0.01% soybean trypsin inhibitor, and 1 mM
phenylmethylsulfonyl fluoride, and were stored at
80 °C until use.
Functional Characterization of Receptor Probes--
Each probe
was functionally characterized to determine its ability to bind to the
CCK receptor and to stimulate intracellular signaling in CCK
receptor-bearing cells. CCK receptor-binding activity was determined in
a standard competition binding assay, using conditions that were
previously established (17). For this, enriched plasma membranes
prepared from the CHO-CCKR cells (5-15 µg per tube) were mixed with
1-2 pM radioligand (the CCK-like agonist,
125I-D-Tyr-Gly-[(Nle28,31)CCK-26-33],
was used in agonist binding assays, whereas its antagonist analogue,
125I-D-Tyr-Gly-[(D-Trp30,Nle28,31)CCK-26-32]-phenylethyl
ester, was used in antagonist binding assays) in the absence or
presence of increasing concentrations of unlabeled fluorescent
peptides. The tubes were incubated at 25 °C for 1 h to achieve
steady-state binding. Bound radioligand was rapidly separated from free
radioligand using a Skatron cell harvester (Molecular Devices,
Sunnyvale, CA) with receptor binding filtermats. Bound radioactivity
was quantified with a gamma spectrometer. Data were analyzed using the
LIGAND program of Munson and Rodbard (18) and were graphed using the
non-linear least-squares curve-fitting routine in the Prism suite of
programs by GraphPad (San Diego, CA).
The ability of the probes to stimulate or inhibit CCK-stimulated
signaling events was determined using a well-established assay of
intracellular calcium concentration in Fura-2-loaded CHO-CCKR cells
(19). In this assay, ~2 million receptor-bearing cells were loaded
with 5 µM Fura-2AM in Ham's F-12 medium for 30 min at
37 °C. Cells were then washed and stimulated with varied concentrations of the receptor probes at 37 °C, and fluorescence was
quantified in a Perkin-Elmer Life Science LS50B luminescence spectrophotometer. Emission was determined at 520 nm after excitation at 340 and 380 nm, and calcium concentration was calculated from the
ratio of the two intensities (20). The peak intracellular calcium
concentration was utilized to determine the agonist concentration dependence of this biological response. For antagonists, after demonstrating the absence of intracellular calcium responses in cells
that were directly stimulated with these compounds, their abilities to
inhibit CCK-stimulated calcium responses were determined in mixing
experiments. In these assays, a constant stimulatory concentration of
CCK (0.1 nM) was used in conjunction with increasing concentrations of the potential antagonist probes in standard intracellular calcium assays.
Fluorescence Spectroscopy--
Steady-state fluorescence spectra
were recorded using a SPEX Fluorolog spectrofluorophotometer (SPEX
industries, Edison, NJ) at 20 °C using a 1-ml quartz cuvette. Unless
stated otherwise, fluorescence measurements were made using cell
membrane preparations at ambient temperature. Solvents and buffers were
degassed by bubbling nitrogen to prevent quenching of fluorescence by
soluble oxygen. Under the conditions employed, fluorescence emission
was also stable to photobleaching.
For measurements of the fluorescence of receptor-bound probes, CCK
receptors on CHO-CCKR cell membranes (50 µg) were allowed to bind
fluorescent probe during incubation at room temperature for 20 min in
KRH buffer, pH 7.4. This suspension was then cooled, and the membranes
were separated by centrifugation at 20,000 × g for 10 min at 4 °C. The ligand-bound membrane fraction was then washed with
iced buffer, centrifuged, and resuspended in cold KRH buffer for
fluorescence measurements. This was accomplished with the membranes
held in suspension with continuous stirring. Fluorescence emission
spectra were rapidly acquired from these samples to ensure maximal
ligand occupation of the receptor. Analogous incubations and
measurements were performed with cell membranes that had not been
exposed to the fluorescent probes. The latter were used to determine
the effects of light scattering and background on the measurements,
with these data subtracted from the experimental sample spectra.
Full fluorescence emission spectra were acquired for each of the probes
free in aqueous solution and bound to the CCK receptor (in the absence
or presence of 100-fold molar excess of non-fluorescent CCK as a
competitor to saturate the receptor). For fluorescence collisional
quenching, anisotropy, and lifetime studies, we utilized the following
pairs of excitation and emission wavelengths (with 6.8-nm bandwidth):
acrylodan, 380 and 455 nm; NBD, 470 and 542 nm; and
Alexa488, 482 and 518 nm.
Collisional Quenching Experiments--
Fluorescence quenching
with the hydrophilic reagent, potassium iodide (KI), was performed as
follows. Samples with receptor-bound fluorescent probe (50 µg of
membrane protein per tube) were prepared as described above.
Fluorescence was measured (using appropriate wavelengths noted above)
after sequential additions to the cuvette of freshly prepared KI (1 M stock in 10 mM
Na2S2O3 to prevent air-induced
oxidation of the iodide). The dilution and ionic strength effects on
fluorescence were calibrated by adding 1 M potassium chloride (KCl) to the control sample and measuring the fluorescence. Corrected data were plotted according to the Stern-Volmer equation, Fo/F = 1 + KSV[Q], where
Fo/F is the ratio of fluorescence
intensity in the absence and presence of iodide. The Stern-Volmer
quenching constant, KSV, was determined from the
slope of Fo/F as a function of the
iodide concentration [I
]. This value was then utilized
with the value of the average fluorescence lifetime (

, as
described below) to determine the bimolecular quenching constant
Kq (Kq = Ksv/

).
Fluorescence Anisotropy Measurements--
Steady-state
anisotropy measurements were recorded using an Edinburgh
spectrofluorophotometer equipped with polarizers and a thermostatically
regulated cuvette. Measurements were performed with constant optimal
wavelengths for excitation and emission of each fluorophore that are
noted above. Emission intensities were measured with excitation-side
polarizer in the vertical position (V) and emission-side polarizer in
the horizontal (H) and vertical (V) positions. Excitation wavelengths
were 380 nm for acrylodan, 470 nm for NBD, and 482 nm for Alexa. In
each situation, this was in a region of relative plateau at or near the
maximum in the absorbance spectrum of the probe. The measurements were
performed at 4 °C, 20 °C, and 37 °C. Anisotropy was calculated
according to the equation, A = (IVV
GIVH)/(IVV + 2GIVH), where IVV is the
intensity measured with both the excitation-side and emission-side polarizers in the vertical positions, and IVH is
the intensity measured with the excitation-side polarizer in the
vertical position and the emission-side polarizer in the horizontal
position. The value of G was calculated by the equation,
G = IHH/IHV.
Fluorescence Lifetime Measurements Using Time-resolved
Fluorescence Spectroscopy--
Fluorescence lifetimes were measured by
use of time-correlated single photon counting (21, 22). Receptor-bound
probes were analyzed in a cuvette with a path length of 1 cm. Samples were excited using a pulse-picked, frequency-doubled titanium-sapphire picosecond laser source (Coherent Mira 900, Palo Alto, CA).
Fluorescence emission was collected through interference filters with
6.8-nm bandwidth. Measurements were taken at 25 °C. The excitation
wavelength was tunable (depending on the fluorophore to be analyzed)
with a pulse width of ~2 ps full-width half-maximum. Data were
collected in 1080 channels, with a width of 10.05 ps/channel.
Fluorescence intensity decay analysis was performed using the GLOBALS
Unlimited program package (23). Models of a single exponential and two discrete exponential lifetime components were utilized. The quality of
fit was judged by the value of Chi-square (
2) statistics.
We assumed the fluorescence decay to be a sum of discrete exponentials,
as in,
|
(Eq. 1)
|
where I(t) is the intensity decay,
i is the decay time of the ith component, and
i is a weighting factor (amplitude) representing the
contribution of the particular lifetime component to the fluorescence decay. The decay parameters were obtained using the
non-linear least squares iterative fitting procedure based on the
Marquardt algorithm. The fractional fluorescence of the ith
component at wavelength
(
i(
)) was calculated
from,
|
(Eq. 2)
|
The mean average lifetime (

) for the bi-exponential
decays of fluorescence were calculated with,
|
(Eq. 3)
|
where 

is the average lifetime,
i is the
fraction of the ith decay component, and
i is
the correspondent lifetime of the ith decay component.
Statistical Analysis--
Data were analyzed using Student's
t test for unpaired values. Significant differences were
considered to be at the p < 0.05 level.
 |
RESULTS |
Characterization of Fluorescent Agonist and Antagonist Probes of
the CCK Receptor--
Each of six fluorescent ligand probes were
synthesized and purified to homogeneity by reversed-phase HPLC. Their
structures were confirmed by mass spectroscopy.
These probes were also studied functionally. Each was found to bind to
the CCK receptor saturably and specifically, with high affinity.
Competition binding curves are shown in Fig.
2, with pharmacological binding
parameters listed in Table I. The three fluorescence analogues of the agonist peptide,
Gly-[(Nle28,31)CCK-26-33] (14), were indeed shown to be
able to stimulate full intracellular calcium responses in CCK
receptor-bearing cells, not different from maximal responses to CCK
itself (Fig 3 and Table I). The three
fluorescent analogues of the antagonist peptide, Gly-[(D-Trp30,Nle28,31)CCK-26-32]-phenylethyl
ester (15), were not able to stimulate any increase in intracellular
calcium in these cells using ligand concentrations as high as 1 µM. Furthermore, when these peptides were used in
conjunction with CCK, they inhibited CCK-stimulated intracellular
calcium responses in a concentration-dependent manner (Fig.
3 and Table I).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 2.
Binding characteristics of fluorescent CCK
receptor probes. Shown are curves reflecting the
concentration dependence for each of the fluorescent probes to compete
for the binding of CCK analogue radioligands to membranes from CHO-CCKR
cells. CCK and the fluorescent agonists were used to compete for
binding of the full agonist radioligand, whereas D-Trp-OPE
and the fluorescent antagonists were used to compete for binding of the
antagonist radioligand. Values reflect saturable binding as a
percentage of control binding in the absence of competitor. Points
represent means ± S.E. of data from three independent experiments
performed in duplicate.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 3.
Ability of fluorescent CCK receptor probes to
stimulate a biological response. Shown are the concentration
dependences for each of the probes to stimulate an intracellular
calcium response in CHO-CCKR cells. Agonists are shown in the
left panel and antagonists in the right panel.
For each of the antagonists, there was no detectable increase in
intracellular calcium using concentrations as high as 1 µM. The plotted curves represent intracellular
calcium responses to the noted concentrations of D-Trp-OPE
or fluorescent antagonist probe used in conjunction with the fixed
concentration of 0.1 nM CCK. Values represent means ± S.E. of data from three independent experiments.
|
|
Fluorescence Emission Spectra for Receptor Probes--
Fig.
4 illustrates the fluorescence emission
spectra for each of the fluorescent probes, when free in aqueous
solution and when bound to the CCK receptor. The acrylodan probes were
most sensitive to their environment, demonstrating the most marked spectral shifts. The maximum emission shifted from 470 nm while in
solution to 454 nm for the bound agonist and 448 nm for the bound
antagonist. Spectra were also acquired for the probes in a series of
solvents having distinct polarities (aqueous, acetonitrile, Me2SO, and n-butanol). The Alexa fluorescence
intensity decreased with decreasing polarity of the solvent,
whereas the fluorescence intensities of the acrylodan and NBD increased
in solvents of decreasing polarity (data not shown).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 4.
Fluorescence emission spectra for probes
utilized in this series of studies. Shown are the regions of
maximal fluorescence emission for each of the fluorescent probes
utilized in this study. Also shown are representative spectra for the
probes in solution (similar for agonist and antagonist probes, with
only agonist probes illustrated), as well as for the probes bound to
CCK receptors in CHO-CCKR cell membranes in the absence or presence of
competing non-fluorescent agonist or antagonist. Probes were excited
with the noted wavelengths: Alexa, 482 nm; acrylodan, 380 nm; NBD, 470 nm.
|
|
Collisional Quenching of Fluorescent Ligands When Bound to the CCK
Receptor--
This series of experiments was performed to further
characterize the environment of each of the fluorophores at the amino terminus of ligands when bound to the CCK receptor. Fig.
5 shows Stern-Volmer plots for the
quenching of the fluorescence of each of the receptor probes using the
aqueous-phase reagent, potassium iodide. The bimolecular quenching
constant values (Kq), shown in Table
II, correlate with extent of solvent
exposure. The nature of the fluorophore in this position within the
ligand appears to be the major determinant of its environment, with the
most hydrophilic indicator, Alexa, much more readily quenched by iodide than the more hydrophobic indicators. This suggests that that the
position at the amino terminus of the probes, just outside of the
pharmacophoric region, allows some mobility of these fluorophores without interfering with the binding or functional characteristics of
the probes. The other consistent observation is the higher value of
Kq for each of the fluorophores when part of a
full agonist than that when in an analogous position in the antagonist.
This is true for each of the three fluorophores, despite their
individual differences in hydrophobicity and the impact of this on
their microenvironment. This suggests that this position within the ligands moves into a less protected environment that is more amenable to iodide quenching upon receptor activation, than the analogous position in the antagonist occupying an inactive conformation of the
receptor. Table II also includes values of Kq
for each of these probes when free in aqueous solution.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 5.
Collisional quenching of fluorescence.
Shown are Stern-Vollmer plots of the concentration dependence of iodide
quenching of the fluorescence of each of the agonist and antagonist
probes when bound to the CCK receptor on CHO-CCKR cell membranes. Data
are expressed as means ± S.E. of values from a minimum of four
independent experiments.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Quenching of fluorescent probes by iodide
Values are expressed as means ± S.E. of data from at least four
independent experiments.
|
|
Anisotropy of Fluorescent Ligands Bound to the CCK
Receptor--
Fluorescence anisotropy reflects the degree of
rotational freedom of the fluorophore incorporated into each of the
ligands (1, 24). Fig. 6 shows the
fluorescence anisotropy of each of the probes when bound to the CCK
receptor. Once again, the character of the fluorophore on the
receptor-bound probe affected this measurement. The more hydrophilic
Alexa, which we know to be more exposed to the aqueous solvent than the
more hydrophobic indicators, also had lower anisotropy at 20 °C and
37 °C, supporting greater rotational freedom for this than for the
other indicators. As expected, as temperature increased, the anisotropy
was found to decrease for each given probe. Of note, for each
fluorophore, the anisotropy was lower at 20 °C when incorporated
into an agonist than when in an analogous position within an antagonist
ligand at the same temperature. This was also true for the acrylodan and NBD probes at 37 °C. There were no significant differences in
fluorescence anisotropy for receptor-bound agonist and antagonist probes having the same indicator when studied at 4 °C.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
Fluorescence anisotropy. Shown are
values for steady-state fluorescence anisotropy of receptor-bound forms
of each of the fluorescent CCK receptor probes determined at three
different temperatures. Data represent means ± S.E. of data from
a minimum of three independent experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001 for a given fluorescent agonist versus antagonist probe at
the same temperature.
|
|
Lifetime Measurements for Fluorescent Ligands Bound to the CCK
Receptor--
Fluorescence lifetimes for each of the probes are shown
in Table III. The fluorescence decay was
resolved into two exponential components for this analysis. Best fits
for these data were supported by
2 values. Once again,
the average lifetimes reflected the hydrophobicity of the fluorophores,
with the more hydrophilic Alexa probes having shorter lifetimes than
the more hydrophobic acrylodan and NBD probes. This is consistent with
the greater exposure of the Alexa to the aqueous solvent and to its
greater anisotropy described above. Once again, the lifetime
measurements showed consistent differences when the same fluorophore
was in the analogous position in agonist and antagonist, with each
lifetime found to be shorter on the agonist probe.
View this table:
[in this window]
[in a new window]
|
Table III
Lifetimes of fluorescent probes
Values are expressed as means ± S.E. of data from a minimum of
four experiments. The agonist fluorophores had significantly shorter
lifetimes than the analogous antagonist fluorophores when bound to the
CCK receptor.
|
|
Incubation of receptor-bearing cell membranes with the non-hydrolyzable
GTP analogue, 1 µM GppNHp, shifted the agonist-bound receptor into its low affinity (inactive) state (10). Repeating the
fluorescence lifetime studies under these conditions demonstrated that
the lifetimes of each of the fluorophores were significantly lengthened, shifting from the values present in the active, high affinity state of the receptor toward those found for the inactive state of the receptor (antagonist probe values) (Table III).
 |
DISCUSSION |
A detailed understanding of the molecular basis of ligand binding
to and activation of G protein-coupled receptors can be gleaned from
complementary information provided by a variety of experimental
techniques. These range from low resolution techniques such as sequence
analysis to more detailed, yet indirect, structure-activity studies of
ligands and receptors. Photoaffinity labeling of receptor regions and
residues adds still more direct information, and the most detailed, yet
least common, insights are to be found in the application of
biophysical techniques. Although biophysical studies like NMR and
crystallography can only be applied to molecules that can be purified
to homogeneity in large amounts, like rhodopsin (2, 25), fluorescence
in principle can be applied much more generally across the G
protein-coupled receptor superfamily.
In this work, we have utilized fluorescence to gain insights into the
peptide ligand-binding region of the CCK receptor. In particular, we
have used this approach to extend our understanding of this microdomain
by assessing the types of molecular motion that agonist and antagonist
ligands undergo when bound to this site.
Like most receptors for peptide ligands in this superfamily,
extracellular tail and loop regions have been shown to be important for
CCK binding (3, 5-7). Evidence includes both receptor mutagenesis and
photoaffinity labeling studies. Even considering that this receptor is
in the rhodopsin-
adrenergic receptor family that has the most
detailed template for helical confluence of any of the families of G
protein-coupled receptors (2), such data still provide only general
insights into ligand docking.
Indeed, two quite divergent models of CCK occupation of this receptor
have been proposed. One of these is based entirely on indirect evidence
from mutagenesis studies (26-28), whereas the other has utilized both
structure-activity data and extensive experimentally derived
constraints of spatial approximation between residues in ligand and
receptor as shown in a series of photoaffinity labeling studies (5-8).
The former model, proposed by Fourmy and his collaborators (26, 27),
places the carboxyl terminus of CCK as dipping into the intramembranous
confluence of helices, and positions the amino terminus of the peptide
adjacent to the receptor amino-terminal tail region just outside of
transmembrane segment one. Such ligand placement may make it difficult
to accommodate the large and varied fluorophores being utilized in the
current study. It is also noteworthy that transmembrane segment one has been found to be relatively immobile in studies of structurally related
heptahelical proteins such as rhodopsin (29).
In contrast, the latter model proposed by the groups of Miller and
Lybrand (5), places the carboxyl terminus of CCK adjacent to
Trp39 in the amino-terminal tail region just outside of
transmembrane segment one (in the position of the amino terminus of CCK
in the other model (26)). This model places the amino terminus of CCK above the dominant binding groove, between the third extracellular loop
and covered by the glycosylated distal amino-terminal tail of the
receptor (8). This portion of the receptor tail seems to play a role in
protecting the receptor from proteolysis, but, having no other clear
function, apparently can be truncated without further impact (8). With
CCK in this position, there is adequate space for a broad spectrum of
structural modifications of its amino terminus, without interfering
with recognized critical agonist-receptor interactions. Indeed,
structure-activity studies experimentally support this prediction
(11-13). Additionally, transmembrane segment six, situated just below
the amino terminus of CCK in this model, has been identified as a
highly mobile region in rhodopsin and the
2-adrenergic
receptor (30-32).
The current fluorescence studies are a direct extension of a unique
series of photoaffinity labeling studies of this receptor (9). In those
studies, a structurally similar peptide agonist, a partial agonist, and
an antagonist were each modified to accommodate a photolabile
benzoyl-phenylalanine at their amino terminus in position 24 (of the
standard CCK-33 numbering scheme). Each of these peptides retained most
of the critical functional groups that establish specific high affinity
binding of the natural peptide agonist to the CCK receptor.
Modification of only the carboxyl-terminal phenylalanine-amide of CCK
to a phenylethyl ester changed the full agonist to a partial agonist
(33). Additional modification of the L-Trp residue in
position 30 to a D-Trp residue changed this to an
antagonist (15). Indeed, each peptide was able to compete for the
binding of each of the other peptide ligands, supporting their
generally similar position of docking to the receptor. This was further
supported by the covalent labeling of the same general domain of the
CCK receptor by each of these probes, as determined by the pattern of
capillary electrophoresis of labeled fragments after cyanogen bromide
cleavage (9). That domain was definitively identified in a later study
(8).
In the current work, we have synthesized two series of CCK receptor
probes, based on the same full agonist and antagonist peptides
described above. In place of the photolabile site of covalent
attachment in position 24, we placed successively one of three
environmentally sensitive fluorescent reporters in that position. As
was predicted by structure-activity studies (11-13), these
modifications were easily accommodated, with minimal interference with
binding or with the same biological characteristics of the underlying
peptide ligand. These probes were fully characterized chemically and biologically.
The fluorescence studies were quite instructive. It is important to
emphasize that these studies were performed with the receptor in its
natural environment in the cell membrane, and they did not require
reconstitution of a solubilized receptor in artificial membranes that
have the potential problem of proper orientation and folding of this
membrane protein. For each series of peptides, agonists, and
antagonists, the hydrophobicity of the fluorescence indicator seemed
most predictive of the environment in which it resided. The most
hydrophilic indicator was most exposed to the aqueous milieu, being
most easily quenched by iodide and having the shortest fluorescence
lifetime. This further supported the indication from structure-activity
studies that this position was outside of the CCK pharmacophore, and
distinct structural modifications could be tolerated there. The
fluorescence indicator could, therefore, move relative to the binding
cleft to find an optimal complementary domain to accommodate its
chemical characteristics.
Despite each fluorescence indicator having a slightly different
microdomain with differences in accessibility to iodide and fluorescence lifetimes, comparison of pairs of agonist and antagonist having the same fluorescence indicator each demonstrated the identical trend. When attached to the agonist, each indicator was more exposed to
the aqueous milieu, more easily quenched by iodide, and had a shorter
lifetime than when attached to the antagonist. Consistent with this,
the anisotropy studies showed that the fluorophore was more mobile on
the agonist than on the antagonist.
These differences in the microenvironment explored by each of the pairs
of fluorescent agonist and antagonist probes are compatible with two
possibilities. The first represents an absolute difference in the
microenvironment of the amino terminus of the antagonist and agonist
peptides that is determined by the D-amino acid in position
30 of the antagonist in place of the natural L-amino acid
in the analogous agonist peptide. Because this peptide binds to the CCK
receptor with the same high affinity as natural CCK, it is likely that
the conformational change induced by the D-Trp substitution
is not so extreme as to preclude most of the normally interacting
functional groups within the ligand and receptor to still exist. This
argues against a substantial change in position or orientation of the
amino terminus in these agonist and antagonist peptide-receptor complexes.
The second possibility is that the change in receptor conformation that
correlates with its activation by an agonist ligand is the major
determinant of the position of the amino terminus of the probes. This
would suggest that the amino terminus of the agonist moves away from a
somewhat protected environment into a position that is more exposed to
the aqueous milieu than it was in the inactive state of the receptor in
which the antagonist is bound. Because this portion of the agonist
peptide has been shown by photoaffinity labeling studies to reside
above the third extracellular loop domain (8), such movement would be
consistent with an upward motion of transmembrane segment six and/or seven.
Indeed, this type of motion has been postulated to exist during
activation of both the
2-adrenergic receptor and
rhodopsin (30, 34). The molecular mechanism of activation of these
molecules may be quite similar to the CCK receptor, with all three of
these molecules having structural homology and being classified in the same group of G protein-coupled receptors (Class I). Kobilka and his
collaborators (32, 35, 36) have used fluorescence spectroscopy to
monitor ligand-induced changes in the conformation of the
2-adrenergic receptor. These studies have utilized
incorporation of NBD into specific sites within the receptor and have
supported a significant movement of the third and sixth transmembrane
segments in response to agonist. The opposite movement of these
segments was observed after antagonist binding to this receptor (35).
Khorana and Hubbel and their collaborators (37) have used site-specific incorporation of nitroxide spin labels into rhodopsin and have observed
the types of molecular motion associated with transition into
metarhodopsin-II. Application of electron paramagnetic resonance spectroscopy to this molecule also demonstrated the movement of transmembrane segment six (helix F of rhodopsin) toward a more hydrophilic environment.
The series of studies in which the non-hydrolyzable GTP analogue was
used to shift the state of the agonist probe-occupied CCK receptor into
its inactive low affinity state was most consistent with the second
possibility. This treatment resulted in a lengthening of the
fluorescence lifetimes of the agonist probes, shifting toward those of
the analogous antagonist probes. This supports the presence of
conformational changes that correlate with affinity states and with the
active and inactive states of this receptor.
It will be important ultimately to perform time-resolved dynamic
studies of changes in conformation of the receptor as it is being
stably occupied by a single probe. We hope, in the future, to extend
this work toward that goal. Additionally, the characterization of these
probes provided by the current studies becomes quite important to
justify their future use in fluorescence resonance energy transfer
studies. Those studies will allow the possibility of triangulation to
accurately identify the position of each fluorophore relative to
specific positions within the receptor. Those studies, too, have the
potential to distinguish active and inactive conformations of this receptor.
 |
ACKNOWLEDGEMENTS |
We thank Peter J. Callahan, Elizabeth M. Hadac, Eileen Holicky, and Susan Kuntz for technical assistance in
these studies, and Elizabeth M. Hadac and Sara Erickson for help in
preparation of the figures and the manuscript.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants DK32878 (to L. J. M.) and GM34847-16 (to F. G. P.) and the Fiterman Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Center for Basic
Research in Digestive Diseases, Mayo Clinic and Foundation, 200 First
St. SW, Rochester, MN 55905. Tel.: 507-284-0680; Fax: 507-284-0762; E-mail: miller@mayo.edu.
Published, JBC Papers in Press, March 13, 2002, DOI 10.1074/jbc.M201164200
 |
ABBREVIATIONS |
The abbreviations used are:
CCK, cholecystokinin;
HPLC, high performance liquid chromatography;
NBD, 7-nitrobenz-2-oxa-1,3-diazol-4-yl;
acrylodan, 6-acryloyl
2-dimethylaminonapthalene;
CCKR, type A cholecystokinin receptor;
CHO, Chinese hamster ovary;
KRH, Krebs-Ringers-HEPES medium;
ACA, aminocaproic acid;
D-Trp-OPE, Gly-[(D-Trp30,Nle28,31)CCK-26-32]-phenylethyl
ester;
Fmoc, N-(9-fluorenyl)methoxycarbonyl;
GppNHp, guanosine 5'-[
,
-imido]triphosphate trisodium
salt.
 |
REFERENCES |
| 1.
|
Turcatti, G.,
Vogel, H.,
and Chollet, A.
(1995)
Biochemistry
34,
3972-3980[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Palczewski, K.,
Kumasaka, T.,
Hori, T.,
Behnke, C. A.,
Motoshima, H.,
Fox, B. A.,
Trong, I. Le.,
Teller, D. C.,
Okada, T.,
Stenkamp, R. E.,
Yamamoto, M.,
and Miyano, M.
(2000)
Science
289,
739-745[Abstract/Free Full Text]
|
| 3.
|
Ji, T. H.,
Grossmann, M.,
and Ji, I.
(1998)
J. Biol. Chem.
273,
17299-17302[Free Full Text]
|
| 4.
|
Schwartz, T. W.
(1994)
Curr. Opin. Biotech.
5,
434-444[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Ji, Z.,
Hadac, E. M.,
Henne, R. M.,
Patel, S. A.,
Lybrand, T. P.,
and Miller, L. J.
(1997)
J. Biol. Chem.
272,
24393-24401[Abstract/Free Full Text]
|
| 6.
|
Hadac, E. M.,
Pinon, D. I., Ji, Z.,
Holicky, E. L.,
Henne, R.,
Lybrand, T.,
and Miller, L. J.
(1998)
J. Biol. Chem.
273,
12988-12993[Abstract/Free Full Text]
|
| 7.
|
Hadac, E. M., Ji, Z. S.,
Pinon, D. I.,
Henne, R. M.,
Lybrand, T. P.,
and Miller, L. J.
(1999)
J. Med. Chem.
42,
2105-2111[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Ding, X. Q.,
Dolu, V.,
Hadac, E. M.,
Holicky, E. L.,
Pinon, D. I.,
Lybrand, T. P.,
and Miller, L. J.
(2001)
J. Biol. Chem.
276,
4236-4244[Abstract/Free Full Text]
|
| 9.
|
Dong, M.,
Ding, X. Q.,
Pinon, D. I.,
Hadac, E. M.,
Oda, R. P.,
Landers, J. P.,
and Miller, L. J.
(1999)
J. Biol. Chem.
274,
4778-4785[Abstract/Free Full Text]
|
| 10.
|
Molero, X.,
and Miller, L. J.
(1991)
Mol. Pharmacol.
39,
150-156[Abstract]
|
| 11.
|
Bodanszky, M.,
Natarajan, S.,
Hahne, W.,
and Gardner, J. D.
(1977)
J. Med. Chem.
20,
1047-1050[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Bodanszky, M.,
Tolle, J. C.,
Gardner, J. D.,
Walker, M. D.,
and Mutt, V.
(1980)
Int. J. Pept. Protein. Res.
16,
402-411[Medline]
[Order article via Infotrieve]
|
| 13.
|
Miller, L. J.,
Rosenzweig, S. A.,
and Jamieson, J. D.
(1981)
J. Biol. Chem.
256,
12417-12423[Free Full Text]
|
| 14.
|
Pearson, R. K.,
Powers, S. P.,
Hadac, E. M.,
Gaisano, H.,
and Miller, L. J.
(1987)
Biochem. Biophys. Res. Commun.
147,
346-353[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Roettger, B. F.,
Ghanekar, D.,
Rao, R. V.,
Toledo, C.,
Yingling, J.,
Pinon, D.,
and Miller, L. J.
(1997)
Mol. Pharmacol.
51,
357-362[Abstract/Free Full Text]
|
| 16.
|
Powers, S. P.,
Pinon, D. I.,
and Miller, L. J.
(1988)
Int. J. Pept. Protein Res.
31,
429-434[Medline]
[Order article via Infotrieve]
|
| 17.
|
Hadac, E. M.,
Ghanekar, D. V.,
Holicky, E. L.,
Pinon, D. I.,
Dougherty, R. W.,
and Miller, L. J.
(1996)
Pancreas
13,
130-139[Medline]
[Order article via Infotrieve]
|
| 18.
|
Munson, P. J.,
and Rodbard, D.
(1980)
Anal. Biochem.
107,
220-239[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Ganguli, S. C.,
Park, C. G.,
Holtmann, M. H.,
Hadac, E. M.,
Kenakin, T. P.,
and Miller, L. J.
(1998)
J. Pharmacol. Exp. Ther.
286,
593-598[Abstract/Free Full Text]
|
| 20.
|
Grynkiewicz, G.,
Poenie, M.,
and Tsien, R. Y.
(1985)
J. Biol. Chem.
260,
3440-3450[Abstract/Free Full Text]
|
| 21.
|
Ghiggino, K. P.,
Lee, A. G.,
Meech, S. R.,
O'Connor, D. V.,
and Phillips, D.
(1981)
Biochemistry
20,
5381-5389[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Doust, T. A.,
Phillips, D.,
and Porter, G.
(1984)
Biochem. Soc. Trans.
12,
630-632[Medline]
[Order article via Infotrieve]
|
| 23.
|
Beechem, J. M.
(1992)
Methods Enzymol.
210,
37-54[Medline]
[Order article via Infotrieve]
|
| 24.
|
Lakowicz, J. R.
(1980)
J. Biochem. Biophys. Methods
2,
91-119[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Loewen, M. C.,
Klein-Seetharaman, J.,
Getmanova, E. V.,
Reeves, P. J.,
Schwalbe, H.,
and Khorana, H. G.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
4888-4892[Abstract/Free Full Text]
|
| 26.
|
Kennedy, K.,
Gigoux, V.,
Escrieut, C.,
Martinez, J.,
Moroder, L.,
Frehel, D.,
Gully, D.,
Vayse, N.,
and Fourmy, D.
(1997)
J. Biol. Chem.
272,
2920-2926[Abstract/Free Full Text]
|
| 27.
|
Gigoux, V.,
Escrieut, C.,
Fehrentz, J. A.,
Poirot, S.,
Maigret, B.,
Moroder, L.,
Gully, D.,
Martinez, J.,
Vaysse, N.,
and Fourmy, D.
(1999)
J. Biol. Chem.
274,
20457-20464[Abstract/Free Full Text]
|
| 28.
|
Gigoux, V.,
Maigret, B.,
Escrieut, C.,
Silvente-Poirot, S.,
Bouisson, M.,
Fehrentz, J. A.,
Moroder, L.,
Gully, D.,
Martinez, J.,
Vaysse, N.,
and Fourmy, D.
(1999)
Protein Sci.
8,
2347-2354[Abstract]
|
| 29.
|
Altenbach, C.,
Klein-Seetharaman, J.,
Cai, K.,
Khorana, H. G.,
and Hubbell, W. L.
(2001)
Biochemistry
40,
15493-15500[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Farrens, D. L.,
Altenbach, C.,
Yang, K.,
Hubbell, W. L.,
and Khorana, H. G.
(1996)
Science
274,
768-770[Abstract/Free Full Text]
|
| 31.
|
Dunham, T. D.,
and Farrens, D. L.
(1999)
J. Biol. Chem.
274,
1683-1690[Abstract/Free Full Text]
|
| 32.
|
Gether, U.,
Lin, S.,
Ghanouni, P.,
Ballesteros, J. A.,
Weinstein, H.,
and Kobilka, B. K.
(1997)
EMBO J.
16,
6737-6747[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Gaisano, H. Y.,
Klueppelberg, U. G.,
Pinon, D. I.,
Pfenning, M. A.,
Powers, S. P.,
and Miller, L. J.
(1989)
J. Clin. Invest.
83,
321-325[Medline]
[Order article via Infotrieve]
|
| 34.
|
Gether, U.,
and Kobilka, B. K.
(1998)
J. Biol. Chem.
273,
17979-17982[Free Full Text]
|
| 35.
|
Gether, U.,
Lin, S.,
and Kobilka, B. K.
(1995)
J. Biol. Chem.
270,
28268-28275[Abstract/Free Full Text]
|
| 36.
|
Gether, U.,
Ballesteros, J. A.,
Seifert, R.,
Sanders-Bush, E.,
Weinstein, H.,
and Kobilka, B. K.
(1997)
J. Biol. Chem.
272,
2587-2590[Abstract/Free Full Text]
|
| 37.
|
Hubbell, W. L.,
Cafiso, D. S.,
and Altenbach, C.
(2000)
Nat. Struct. Biol.
7,
735-739[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. G. Harikumar, D. I. Pinon, and L. J. Miller
Fluorescent Indicators Distributed throughout the Pharmacophore of Cholecystokinin Provide Insights into Distinct Modes of Binding and Activation of Type A and B Cholecystokinin Receptors
J. Biol. Chem.,
September 15, 2006;
281(37):
27072 - 27080.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Harikumar, K. Hosohata, D. I. Pinon, and L. J. Miller
Use of Probes with Fluorescence Indicator Distributed throughout the Pharmacophore to Examine the Peptide Agonist-binding Environment of the Family B G Protein-coupled Secretin Receptor
J. Biol. Chem.,
February 3, 2006;
281(5):
2543 - 2550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Harikumar and L. J. Miller
Fluorescence Resonance Energy Transfer Analysis of the Antagonist- and Partial Agonist-occupied States of the Cholecystokinin Receptor
J. Biol. Chem.,
May 13, 2005;
280(19):
18631 - 18635.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Harikumar, V. Puri, R. D. Singh, K. Hanada, R. E. Pagano, and L. J. Miller
Differential Effects of Modification of Membrane Cholesterol and Sphingolipids on the Conformation, Function, and Trafficking of the G Protein-coupled Cholecystokinin Receptor
J. Biol. Chem.,
January 21, 2005;
280(3):
2176 - 2185.
[Abstract]
[Full Text]
[PDF]
|
 |
|